Skip to main content
Caplight Logo









Obulytix

Obulytix

Private
BelgiumHealthcare & Life Scienceshttps://www.obulytix.com/

Last Round

Seed

Dec 5, 2023

Total Funding Raised

$4.33M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Obulytix is a biotechnology company developing a novel class of precision biologics designed to selectively target and eliminate drug-resistant bacterial pathogens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

lysin therapeuticsantimicrobial resistanceAMRphage lysinsenzyme-based antibioticsenzybioticsAI drug discoveryprecision biologicssynthetic biologymicrobiome sparingGram-negative bacteriadrug discovery platformphage therapysuperbug crisisAcinetobacter baumannii

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Obulytix Comparables

Compare Obulytix with similar companies based on industry and business-model similarity.

Obulytix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Telum Therapeutics
85%
Astralytix
85%
GangaGen
78%

Obulytix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 5, 2023

Key People

Founding team and executive leadership

Kristof Van Emelen

Chief Executive Officer

Executive Team

Sara Lambrechts

Chief Financial Officer

Executive Team

Obulytix Investors

Notable investors and investment history

Obulytix investors
InvestorRounds
Boehringer Ingelheim Venture FundSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 41% MoM, reaching 1K.

  • Jul 25, 2026

    Monthly visitors increased 128% MoM.

Recent news

Latest coverage and updates

  • is_developingJun 23, 2026

    Obulytix is developing Precision Lysin Therapeutics on Jun 1st '26.

Obulytix Filings

Explore SEC and related filing metadata, where available.

Obulytix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Obulytix's valuation, stock price, and market status.

Is Obulytix a public or private company?

Obulytix is a private company.

What is the current stock price of Obulytix?

Obulytix is a private company with no public stock price. No recent secondary market data is available.

How much is Obulytix worth (valuation)?

Valuation information for Obulytix is not publicly available.

Can I buy Obulytix stock?

Obulytix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Obulytix's last funding round?

Funding round information for Obulytix is not publicly available.

Who are the main investors in Obulytix?

Investor information for Obulytix is not publicly disclosed.

Will Obulytix IPO soon?

No public IPO plans have been announced for Obulytix.

How can I track Obulytix secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Obulytix's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBelgium
Employee Range18
Year Founded2023
Last FundingDec 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?